Curcumin/Ag conjugated nanoparticles confer neuroprotection against hyoscine-induced acute psychosis: behavioral and biochemical evidence

Articles in Press

Document Type : Research Paper

Authors

1 Department of Pharmaceutical Chemistry, Faculty of Pharmaceutical Chemistry, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran

2 University of South Florida College of Public Health, Tampa, FL, USA and Institute for Integrative Toxicology, Michigan State University, East Lansing, MI, USA

3 Pediatric Respiratory Disease Research Center, National Research Institute of Tuberculosis and Lung Disease, Shahid Beheshti University of Medical Sciences, Tehran, Iran

4 Department of Organic Chemistry, Faculty of Pharmaceutical Chemistry, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran

Abstract

Obejctive(s): Psychosis is a prevalent psychiatric disorder. Chemicals that modulate the dopaminergic system have been the primary treatment, but these drugs have not always been effective, and some have deleterious side effects. During the last several years, a concerted effort has been made to advance the development of novel pharmaceuticals, utilizing approaches such as nanotechnology, natural compounds, and Eastern medicinal practices. Nanotechnology, including Ag-based nanoparticles, is an exciting option for optimizing drug performance, including reduced side effects and improved pharmacological and clinical profiles. The impact of curcumin‐Ag conjugated nanoparticles (Cur/Ag NPs)  was evaluated in a rodent model of psychosis.
Materials and Methods: Cur/Ag NPs were synthesized and characterized by FTIR, FE-SEM, EDX, and UV-vis spectrophotometry. The effect of Cur-Ag NPs was determined for several psychosis-related behaviors (Yawning number, rearing number, and stereotype score) and blood levels of the inflammatory factors CRP, TNF-α, and IL-1β, and cortisol in an animal model of hyoscine-induced psychosis.
Results: Cur/Ag NPs modulated the Yawning number, rearing number, and stereotypic score in hyoscine-induced acute psychosis and attenuated the blood levels of inflammatory parameters, including TNF-α, IL-1β, C-reactive protein, and cortisol. Cur/Ag NPs demonstrated greater efficacy compared to curcumin, altering these effects at lower concentrations.
Conclusion: Cur/Ag NPs and Curcumin were effective in a mouse model of psychosis, exhibiting protective effects against hyoscine-induced acute psychosis, and may be potential candidates for further clinical investigation for treating psychosis-related behavior.    

Keywords

References

  1. Bishop JR, Zhang L, Lizano P. Inflammation subtypes and translating inflammation-related genetic findings in schizophrenia and related psychoses: a perspective on pathways for treatment stratification and novel therapies. Harv Rev Psychiatry. 2022;30(1):59-70.
  2. Williams JA, Burgess S, Suckling J, Lalousis PA, Batool F, Griffiths SL, et al. Inflammation and brain structure in schizophrenia and other neuropsychiatric disorders: a Mendelian randomization study. JAMA Psychiatry. 2022;79(5):498-507.
  3. Arciniegas DB. Psychosis. Continuum (Minneap Minn). 2015;21(3):715-736.
  4. Bebbington P. Unravelling psychosis: psychosocial epidemiology, mechanism, and meaning. Shanghai Arch Psychiatry. 2015;27(2):70.
  5. De Oliveira IR, Juruena M. Treatment of psychosis: 30 years of progress. J Clin Pharm Ther. 2006;31(6):523-534.
  6. Demjaha A, Lappin J, Stahl D, Patel M, MacCabe J, Howes O, et al. Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors. Psychol Med. 2017;47(11):1981-1989.
  7. Barak S, Weiner I. Towards an animal model of an antipsychotic drug-resistant cognitive impairment in schizophrenia: scopolamine induces abnormally persistent latent inhibition, which can be reversed by cognitive enhancers but not by antipsychotic drugs. Int J Neuropsychopharmacol. 2009;12(2):227-241.
  8. Blokland A. Cholinergic models of memory impairment in animals and man: scopolamine vs. biperiden. Behav Pharmacol. 2022;33(4):231-237.
  9. Barak S, Weiner I. Scopolamine induces disruption of latent inhibition which is prevented by antipsychotic drugs and an acetylcholinesterase inhibitor. Neuropsychopharmacology. 2007;32(5):989-999.
  10. Ham S, Kim TK, Chung S, Im HI. Drug abuse and psychosis: new insights into drug-induced psychosis. Exp Neurobiol. 2017;26(1):11-20.
  11. Forrest AD, Coto CA, Siegel SJ. Animal models of psychosis: current state and future directions. Curr Behav Neurosci Rep. 2014;1(2):100-116.
  12. Piontkewitz Y, Arad M, Weiner I. Tracing the development of psychosis and its prevention: what can be learned from animal models. Neuropharmacology. 2012;62(3):1273-1289.
  13. Winship IR, Dursun SM, Baker GB, Balista PA, Kandratavicius L, Maia-de-Oliveira JP, et al. An overview of animal models related to schizophrenia. Can J Psychiatry. 2019;64(1):5-17.
  14. Jones CA, Watson D, Fone K. Animal models of schizophrenia. Br J Pharmacol. 2011;164(4):1162-1194.
  15. Geyer MA, Moghaddam B. Animal models relevant to schizophrenia disorders. Neuropsychopharmacology. 2002;50:690-701.
  16. Yadav M, Parle M, Jindal DK, Sharma N. Potential effect of spermidine on GABA, dopamine, acetylcholinesterase, oxidative stress and proinflammatory cytokines to diminish ketamine-induced psychotic symptoms in rats. Biomed Pharmacother. 2018;98:207-213.
  17. Emorinken A, Akpasubi BO, Izirein HO, Oyerinde A. Acute-onset psychosis induced by a therapeutic dose of parenteral hyoscine butylbromide: a case report. Indian J Case Reports. 2023;9(3):65-67.
  18. Mongan D, Ramesar M, Focking M, Cannon M, Cotter D. Role of inflammation in the pathogenesis of schizophrenia: a review of the evidence, proposed mechanisms and implications for treatment. Early Interv Psychiatry. 2020;14(4):385-397.
  19. Bergink V, Gibney SM, Drexhage HA. Autoimmunity, inflammation, and psychosis: a search for peripheral markers. Biol Psychiatry. 2014;75(4):324-331.
  20. Al-Diwani AA, Pollak TA, Irani SR, Lennox BR. Psychosis: an autoimmune disease? Immunology. 2017;152(3):388-401.
  21. Mondelli V, Ciufolini S, Belvederi Murri M, Bonaccorso S, Di Forti M, Giordano A, et al. Cortisol and inflammatory biomarkers predict poor treatment response in first episode psychosis. Schizophr Bull. 2015;41(5):1162-1170.
  22. Fusar-Poli P, Davies C, Solmi M, Brondino N, De Micheli A, Kotlicka-Antczak M, et al. Preventive treatments for psychosis: umbrella review (just the evidence). Front Psychiatry. 2019;10:764.
  23. Hoenders HR, Bartels-Velthuis AA, Vollbehr NK, Bruggeman R, Knegtering H, de Jong JT. Natural medicines for psychotic disorders: a systematic review. J Nerv Ment Dis. 2018;206(2):81-101.
  24. Otimenyin SO, Ior LD. Medicinal plants used in the management of psychosis. In: Complementary Therapies. IntechOpen; 2021.
  25. Miodownik C, Lerner V, Kudkaeva N, Lerner PP, Pashinian A, Bersudsky Y, et al. Curcumin as add-on to antipsychotic treatment in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol. 2019;42(4):117-122.
  26. Kucukgoncu S, Guloksuz S, Tek C. Effects of curcumin on cognitive functioning and inflammatory state in schizophrenia: A double-blind, placebo-controlled pilot trial. J Clin Psychopharmacol. 2019;39(2):182-184.
  27. Sudakaran SV, Venugopal JR, Vijayakumar GP, Abisegapriyan S, Grace AN, Ramakrishna S. Sequel of MgO nanoparticles in PLACL nanofibers for anticancer therapy in synergy with curcumin/β-cyclodextrin. Mater Sci Eng C. 2017;71:620-628.
  28. Motaghinejad M, Bangash MY, Hosseini P, Karimian SM, Motaghinejad O. Attenuation of morphine withdrawal syndrome by various dosages of curcumin in comparison with clonidine in mouse: possible mechanism. Iran J Med Sci. 2015;40(2):125.
  29. Ahmadinasab H, Motaghinejad M, Nosratabad BA, Bozorgniahosseini S, Rostami P, Jafarabadi GS, et al. Hepatoprotection effect of curcumin against methylphenidate-induced hepatotoxicity: histological and biochemical evidences. Int J Prev Med. 2022;13(1):65.
  30. Mobinhosseini F, Salehirad M, Wallace Hayes A, Motaghinejad M, Hekmati M, Safari S, et al. Curcumin-ZnO conjugated nanoparticles confer neuroprotection against ketamine-induced neurotoxicity. J Biochem Mol Toxicol. 2024;38(1):e23611.
  31. Adibipour F, Salehirad M, Hayes AW, Hekmati M, Motaghinejad M. Preventive effect of ZnO-metformin nanocomposite against carbon tetrachloride-induced hepatotoxicity. Nanomed Res J. 2024;9(2):155-163.
  32. Kheiri R, Koohi MK, Sadeghi-Hashjin G, Nouri H, Khezli N, Hassan MA, et al. Comparison of the effects of iron oxide, as a new form of iron supplement, and ferrous sulfate on the blood levels of iron and total iron-binding globulin in the rabbit. Iran J Med Sci. 2017;42(1):79.
  33. Rai M, Pandit R, Gaikwad S, Yadav A, Gade A. Potential applications of curcumin and curcumin nanoparticles: from traditional therapeutics to modern nanomedicine. Nanotechnol Rev. 2015;4(2):161-172.
  34. Moniruzzaman M, Min T. Curcumin, curcumin nanoparticles and curcumin nanospheres: a review on their pharmacodynamics based on monogastric farm animal, poultry and fish nutrition. Pharmaceutics. 2020;12(5):447.
  35. Runjun S, Kumar DM, Lakshi S, Anand R, Ratul S. Conjugation of curcumin with Ag nanoparticle for improving its bioavailability and study of the bioimaging response. Nanosyst Phys Chem Math. 2021;12(4):528-535.
  36. El Khoury E, Abiad M, Kassaify ZG, Patra D. Green synthesis of curcumin-conjugated nanosilver for applications in nucleic acid sensing and antibacterial activity. Colloids Surf B Biointerfaces. 2015;127:274-280.
  37. Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. J Cereb Blood Flow Metab. 2020;40(9):1769-1777.
  38. Sadeghi R, Razzaghdoust A, Bakhshandeh M, Nasirinezhad F, Mofid B. Nanocurcumin as a radioprotective agent against radiation-induced mortality in mice. Nanomed J. 2019;6(1)
  39. Jantawong C, Priprem A, Intuyod K, Pairojkul C, Pinlaor P, Waraasawapati S, et al. Curcumin-loaded nanocomplexes: acute and chronic toxicity studies in mice and hamsters. Toxicol Rep. 2021;8:1346-1357.
  40. Abbas MM. The effect of hyoscine on serum serotonin and acetylcholine levels and their impacts on neurobehavior in mice. Egypt J Vet Sci. 2024;1:1-6.
  41. Hosseinzadeh H, Ramezani M, Akhtar Y, Ziaei T. Effects Boswellia carterii gum resin fractions on intact memory and hyoscine-induced learning impairments in rats performing the morris water maze task. Med Plants. 2010;9(34):95-101.
  42. Furuie H, Yamada K, Ichitani Y. MK-801-induced and scopolamine-induced hyperactivity in rats neonatally treated chronically with MK-801. Behavioural Pharmacology. 2013;24(8):678-683.
  43. Arruda MdOV, Soares PM, Honório JER, Lima RCdS, Chaves EMC, Lobato RDFG, et al. Activities of the antipsychotic drugs haloperidol and risperidone on behavioural effects induced by ketamine in mice. Sci Pharm. 2008;76(4):673-688.
  44. Tada M, Shirakawa K, Matsuoka N, Mutoh S. Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine. Psychopharmacology (Berl). 2004;176(1):94-100.
  45. Motaghinejad M, Motevalian M, Shabab B. Possible involvements of glutamate and adrenergic receptors on acute toxicity of methylphenidate in isolated hippocampus and cerebral cortex of adult rats. Fundamental & Clinical Pharmacology. 2017;31(2):208-225.
  46. Motaghinejad O, Motaghinejad M, Motevalian M, Rahimi-Sharbaf F, Beiranvand T. The effect of maternal forced exercise on offspring pain perception, motor activity and anxiety disorder: the role of 5-HT2 and D2 receptors and CREB gene expression. J Exerc Rehabil. 2017;13(5):514-521
  47. Salehirad M, Hayes AW, Motaghinejad M, Gholami M. Protective effects of curcumin/magnesium oxide nanoparticles on ketamine-induced neurotoxicity in the mouse hippocampus. Res Pharm Sci. 2025;20(3):416-433.
  48. Mach CM, Mathew L, Mosley SA, Kurzrock R, Smith JA. Determination of minimum effective dose and optimal dosing schedule for liposomal curcumin in a xenograft human pancreatic cancer model. Anticancer Res. 2009;29(6):1895-1899.
  49. Tiwari DK, Jin T, Behari J. Dose-dependent in-vivo toxicity assessment of silver nanoparticle in Wistar rats. Toxicol Mech Methods. 2011;21(1):13-24.
  50. Perkasa DP, Arozal W, Kusmardi K, Syaifudin M, Purwanti T, Laksmana RI, et al. Toxicity and biodistribution of alginate-stabilized AgNPs upon 14-days repeated dose oral administration in mice. Appl Pharm Sci. 2024;14(6):135-146.
  51. Mohammadi E, Amini SM, Mostafavi SH, Amini SM. An overview of antimicrobial efficacy of curcumin-silver nanoparticles. Nanomed Res J. 2021;6(2):105-111.
  52. Loo C-Y, Rohanizadeh R, Young PM, Traini D, Cavaliere R, Whitchurch CB, et al. Combination of silver nanoparticles and curcumin nanoparticles for enhanced anti-biofilm activities. J Agric Food Chem. 2016;64(12):2513-2522.
  53. Monisha K, Shilpa SA, Anandan B, Hikku G. Ethanolic curcumin/silver nanoparticles suspension as antibacterial coating mixture for gutta-percha and cotton fabric. Eng Res Express. 2023;5(2):025054.
  54. Stedenfeld KA, Clinton SM, Kerman IA, Akil H, Watson SJ, Sved AF. Novelty-seeking behavior predicts vulnerability in a rodent model of depression. Physiol Behav. 2011;103(2):210-216.
  55. Ghafarimoghadam M, Mashayekh R, Gholami M, Fereydani P, Shelley-Tremblay J, Kandezi N, et al. A review of behavioral methods for the evaluation of cognitive performance in animal models: current techniques and links to human cognition. Physiol Behav. 2022;244:113652.
  56. Yadav M, Kumar A. Behavioural and Non-behavioural Experimental Models of Psychosis: Current State and Future Aspects. Animal Models for Neurological Disorders. 2021:65-77.
  57. Li S-M, Collins GT, Paul NM, Grundt P, Newman AH, Xu M, et al. Yawning and locomotor behavior induced by dopamine receptor agonists in mice and rats. Behav Pharmacol. 2010;21(3):171-181.
  58. Daquin G, Micallef J, Blin O. Yawning. Sleep Med Rev. 2001;5(4):299-312.
  59. Kostrzewa RM, Kostrzewa JP, Kostrzewa RA, Kostrzewa FP, Brus R, Nowak P. Stereotypic progressions in psychotic behavior. Neurotox Res. 2011;19:243-252.
  60. Dahlen A, Zarei M, Melgoza A, Wagle M, Guo S. THC-induced behavioral stereotypy in zebrafish as a model of psychosis-like behavior. Sci Rep. 2021;11(1):15693.
  61. Martin RS, Secchi RL, Sung E, Lemaire M, Bonhaus DW, Hedley LR, et al. Effects of cannabinoid receptor ligands on psychosis-relevant behavior models in the rat. Psychopharmacology (Berl). 2003;165:128-135.
  62. Gong S, Miao Y-L, Jiao G-Z, Sun M-J, Li H, Lin J, et al. Dynamics and correlation of serum cortisol and corticosterone under different physiological or stressful conditions in mice. PLoS One. 2015;10(2):e0117503.
  63. Sentari M, Harahap U, Sapiie TWA, Ritarwan K. Blood cortisol level and blood serotonin level in depression mice with basil leaf essential oil treatment. Open Access Maced J Med Sci. 2019;7(16):2652.
  64. Bose U, Broadbent JA, Juhász A, Karnaneedi S, Johnston EB, Stockwell S, et al. Protein extraction protocols for optimal proteome measurement and arginine kinase quantitation from cricket Acheta domesticus for food safety assessment. Food Chem. 2021;348:129110.
  65. Fernández-Vizarra E, Fernández-Silva P, Enríquez JA. Isolation of mitochondria from mammalian tissues and cultured cells. In: Cell Biology. Elsevier; 2006; 69-77.
  66. Kruger NJ. The Bradford method for protein quantitation. In: The Protein Protocols Handbook. 2009:17-24.
  67. Kirby DM, Thorburn DR, Turnbull DM, Taylor RW. Biochemical assays of respiratory chain complex activity. Methods Cell Biol. 2007;80:93-119.
  68. Bénit P, Goncalves S, Dassa EP, Brière J-J, Martin G, Rustin P. Three spectrophotometric assays for the measurement of the five respiratory chain complexes in minuscule biological samples. Clin Chim Acta. 2006;374(1-2):81-86.
  69. Hnasko R. ELISA. Springer; 2015
  70. Crowther JR. The ELISA guidebook. Springer Science & Business Media; 2008.
  71. Willner K, Vasan S, Patel P, Abdijadid S. Atypical antipsychotic agents. StatPearls [Internet]. StatPearls Publishing; 2024.
  72. Meltzer HY, Gadaleta E. Contrasting typical and atypical antipsychotic drugs. Focus. 2021;19(1):3-13.
  73. Misiak B, Bartoli F, Carrà G, Stańczykiewicz B, Gładka A, Frydecka D, et al. Immune-inflammatory markers and psychosis risk: A systematic review and meta-analysis. Psychoneuroendocrinology. 2021;127:105200.
  74. Dunleavy C, Elsworthy RJ, Upthegrove R, Wood SJ, Aldred S. Inflammation in first‐episode psychosis: the contribution of inflammatory biomarkers to the emergence of negative symptoms, a systematic review and meta‐analysis. Acta Psychiatr Scand. 2022;146(1):6-20.
  75. Kose M, Pariante CM, Dazzan P, Mondelli V. The role of peripheral inflammation in clinical outcome and brain imaging abnormalities in psychosis: a systematic review. Front Psychiatry. 2021;12:612471.
  76. Ullah I, Awan HA, Aamir A, Diwan MN, de Filippis R, Awan S, et al. Role and perspectives of inflammation and C-reactive protein (CRP) in psychosis: an economic and widespread tool for assessing the disease. Int J Mol Sci. 2021;22(23):13032.
  77. Zajkowska Z, Mondelli V. First-episode psychosis: an inflammatory state? Neuroimmunomodulation. 2014;21(2-3):102-108.
  78. Fraguas D, Díaz-Caneja CM, Ayora M, Hernández-Álvarez F, Rodríguez-Quiroga A, Recio S, et al. Oxidative stress and inflammation in first-episode psychosis: a systematic review and meta-analysis. Schizophr Bull. 2019;45(4):742-751.
  79. Jeppesen R, Christensen RH, Pedersen EM, Nordentoft M, Hjorthøj C, Köhler-Forsberg O, et al. Efficacy and safety of anti-inflammatory agents in treatment of psychotic disorders–A comprehensive systematic review and meta-analysis. Brain Behav Immun. 2020;90:364-380.
  80. Çakici N, Van Beveren N, Judge-Hundal G, Koola M, Sommer I. An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis. Psychol Med. 2019;49(14):2307-2319.
  81. Hong J, Bang M. Anti-inflammatory strategies for schizophrenia: a review of evidence for therapeutic applications and drug repurposing. Clin Psychopharmacol Neurosci. 2020;18(1):10.
  82. Karthikeyan A, Senthil N, Min T. Nanocurcumin: A promising candidate for therapeutic applications. Front Pharmacol. 2020;11:487.
  83. Hassanizadeh S, Shojaei M, Bagherniya M, Orekhov AN, Sahebkar A. Effect of nano‐curcumin on various diseases: a comprehensive review of clinical trials. Biofactors. 2023;49(3):512-533.
  84. Peng Y, Ao M, Dong B, Jiang Y, Yu L, Chen Z, et al. Anti-inflammatory effects of curcumin in inflammatory diseases: status, limitations and countermeasures. Drug Des Devel Ther. 2021;15:4503-4525.
  85. Hussain Z, Thu HE, Amjad MW, Hussain F, Ahmed TA, Khan S. Exploring recent developments to improve antioxidant, anti-inflammatory and antimicrobial efficacy of curcumin: A review of new trends and future perspectives. Mater Sci Eng C Mater Biol Appl. 2017;77:1316-1326.
  86. Rabiee R, Hosseini Hooshiar S, Ghaderi A, Jafarnejad S. Schizophrenia, curcumin and minimizing side effects of antipsychotic drugs: possible mechanisms. Neurochem Res. 2023;48(3):713-724.
  87. Teleanu DM, Chircov C, Grumezescu AM, Volceanov A, Teleanu RI. Blood-brain delivery methods using nanotechnology. Pharmaceutics. 2018;10(4):269.
  88. Naqvi S, Panghal A, Flora S. Nanotechnology: a promising approach for delivery of neuroprotective drugs. Front Neurosci. 2020;14:494.
  89. Bulut NS, Arpacıoğlu ZB. Acute onset psychosis with complex neurobehavioural symptomatology following the intramuscular injection of hyoscine butylbromide: a case report with an overview of the literature. Eur J Hosp Pharm. 2022;29(5):294-297.
  90. Dold M, Samara MT, Li C, Tardy M, Leucht S. Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders. Cochrane Database Syst Rev. 2015;1:CD009831
  91. Perry BI, Upthegrove R, Thompson A, Marwaha S, Zammit S, Singh SP, et al. Dysglycaemia, inflammation and psychosis: findings from the UK ALSPAC birth cohort. Schizophr Bull. 2019;45(2):330-338.
  92. Park S, Miller BJ. Meta-analysis of cytokine and C-reactive protein levels in high-risk psychosis. Schizophr Res. 2020;226:5-12.
  93. Silva-Buzanello RA, Souza MF, Oliveira DA, Bona E, Leimann FV, Cardozo Filho L, et al. Preparation of curcumin-loaded nanoparticles and determination of the antioxidant potential of curcumin after encapsulation. Polimeros. 2016;26:207-214.
  94. Scuto MC, Mancuso C, Tomasello B, Ontario ML, Cavallaro A, Frasca F, et al. Curcumin, hormesis and the nervous system. Nutrients. 2019;11(10):2417.
  95. Jin W, Botchway BO, Liu X. Curcumin can activate the Nrf2/HO-1 signaling pathway and scavenge free radicals in spinal cord injury treatment. Neurorehabil Neural Repair. 2021;35(7):576-584.
  96. Mittal A, Nagpal M, Vashistha VK, Arora R, Issar U. Recent advances in the antioxidant activity of metal-curcumin complexes: a combined computational and experimental review. Free Radic Res. 2024;58(1):11-26.
  97. Yang C, Han M, Li R, Zhou L, Zhang Y, Duan L, et al. Curcumin nanoparticles inhibiting ferroptosis for the enhanced treatment of intracerebral hemorrhage. Int J Nanomedicine. 2021;16:8049-8065.
  98. Prasad S, DuBourdieu D, Srivastava A, Kumar P, Lall R. Metal–curcumin complexes in therapeutics: an approach to enhance pharmacological effects of curcumin. Int J Mol Sci. 2021;22(13):7094.
  99. Yan H, Wang L, Mu Y. Biosynthesis of Ag/Cu nanocomposite mediated by Curcuma longa: evaluation of its antibacterial properties against oral pathogens. Open Chem. 2024;22(1):20240059.
  100. Khadrawy YA, Hosny EN, Magdy M, Mohammed HS. Antidepressant effects of curcumin-coated iron oxide nanoparticles in a rat model of depression. Eur J Pharmacol. 2021;908:174384.
  101. Yavarpour-Bali H, Ghasemi-Kasman M, Pirzadeh M. Curcumin-loaded nanoparticles: A novel therapeutic strategy in treatment of central nervous system disorders. Int J Nanomedicine. 2019:4449-4460.
  102. He X, Zhu Y, Wang M, Jing G, Zhu R, Wang S. Antidepressant effects of curcumin and HU-211 coencapsulated solid lipid nanoparticles against corticosterone-induced cellular and animal models of major depression. Int J Nanomedicine. 2016:4975-4990.
  103. Sandhir R, Yadav A, Mehrotra A, Sunkaria A, Singh A, Sharma S. Curcumin nanoparticles attenuate neurochemical and neurobehavioral deficits in experimental model of Huntington’s disease. Neuromolecular Med. 2014;16(1):106-118.
  104. Fahmy HM, Aboalasaad FA, Mohamed AS, Elhusseiny FA, Khadrawy YA, Elmekawy A. Evaluation of the therapeutic effect of curcumin-conjugated zinc oxide nanoparticles on reserpine-induced depression in Wistar rats. Biol Trace Elem Res. 2024;202(6):2630-2644.
  105. Naserzadeh P, Hafez AA, Abdorahim M, Abdollahifar MA, Shabani R, Peirovi H, et al. Curcumin loading potentiates the neuroprotective efficacy of Fe3O4 magnetic nanoparticles in cerebellum cells of schizophrenic rats. Biomed Pharmacother. 2018;108:1244-1252.

 

 

Nanomedicine Journal

Articles in Press, Accepted Manuscript
Available Online from 01 February 2026

Files

Share

How to cite

Statistics